Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma.

Blood Adv · 2023 · PMC10111356 · PMID 36534160

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Responders also showed a trend of higher T-cell exposure over the first 28 days after lete-cel infusion (AUC 0-28d ) compared with nonresponders ( Figure 3 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.